Image: Shutterstock

FDA re­vokes EUA for Eli Lil­ly Covid-19 treat­ment

Eli Lil­ly on Fri­day re­quest­ed, and sev­er­al hours lat­er, the FDA re­voked the emer­gency au­tho­riza­tion for its Covid-19 drug bam­lanivimab, which is no longer as ef­fec­tive as a com­bo ther­a­py be­cause of a rise in coro­n­avirus vari­ants across the US.

FDA said it has de­ter­mined that the known and po­ten­tial ben­e­fits of bam­lanivimab, when ad­min­is­tered alone, no longer out­weigh its known and po­ten­tial risks. As of mid-March, the agency said, about 20% of virus­es se­quenced in the US were re­port­ed as vari­ants ex­pect­ed to be re­sis­tant to bam­lanivimab alone, which in­creased from about 5% in mid-Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA